Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Weekly Irinotecan Plus Protracted Venous Fluorouracil Infusion (WI-FI) in Advanced Colorectal Cancer: A Phase II Study

CRISTIANO OLIVA, PAOLO POCHETTINO, PAOLA BERGNOLO, ANTONELLA BOGLIONE, SIMONA CHIADÒ CUTIN, MANUELA INGUÌ, ORIETTA DAL CANTON, FERDINANDO GARETTO, MANUELA BISCARDI, ELISA BERNO and ALESSANDRO COMANDONE
Anticancer Research July 2008, 28 (4C) 2327-2332;
CRISTIANO OLIVA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cristiano.oliva@gmail.com
PAOLO POCHETTINO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PAOLA BERGNOLO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANTONELLA BOGLIONE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SIMONA CHIADÒ CUTIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MANUELA INGUÌ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ORIETTA DAL CANTON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FERDINANDO GARETTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MANUELA BISCARDI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELISA BERNO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALESSANDRO COMANDONE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Irinotecan (IRI) is a topoisomerase I inhibitor active as first- or second-line chemotherapy in advanced colorectal cancer (ACRC). Its combination with fluorouracil (FU) increases the response rate and prolongs survival. In order to identify a new effective and less toxic schedule of administration, we planned this phase II study with weekly IRI and protracted venous infusion of FU (WI-FI regimen). The primary endpoint was the objective response rate. Secondary aims were to detect toxicity, progression-free survival (PFS) and overall survival (OS) of patients (pts). Materials and Methods: On May 2000, a monoinstitutional study commenced with the following schedule of administration: IRI 80 mg/m2 on days 1, 8, 15, 22, 29 plus a 28-day protracted venous infusion of FU 200 mg/m2/day. The treatment was repeated every 35 days. Cycles were administered until a maximum of 6 courses, disease progression or unacceptable toxicity. Results: By March 2005, 52 patients (30 males and 22 females) had entered the study. Their median age was 61.5 years and the median ECOG PS was 1. In total, 223 courses were administered (median 5 cycles/patient). Toxicity was low: neutropenia G3 and asthenia G3 were the most observed toxicities (5 pts each). No other grade 3-4 toxic side-effects were seen. Weekly IRI was interrupted in 11 pts, mostly related to problems with the central venous catheter. Following RECIST criteria, we observed 5 complete responses, 15 partial responses, 17 pts had stable disease, while in 15 disease progressed. The overall response rate was 38.5% and the disease control rate was 71.2% . Thirteen pts underwent surgical resection of their relapsing disease. The median PFS was 8.2 months and the median OS was 16.3 months. Conclusion: The WI-FI regimen is an active treatment with a good safety profile in patients with CRC. The low incidence of grade 3-4 toxicities justifies further evaluation of this combination.

  • Advanced colorectal cancer
  • weekly irinotecan
  • protracted venous infusion fluorouracil

Footnotes

  • Received February 21, 2008.
  • Revision received May 27, 2008.
  • Accepted May 28, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Weekly Irinotecan Plus Protracted Venous Fluorouracil Infusion (WI-FI) in Advanced Colorectal Cancer: A Phase II Study
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Weekly Irinotecan Plus Protracted Venous Fluorouracil Infusion (WI-FI) in Advanced Colorectal Cancer: A Phase II Study
CRISTIANO OLIVA, PAOLO POCHETTINO, PAOLA BERGNOLO, ANTONELLA BOGLIONE, SIMONA CHIADÒ CUTIN, MANUELA INGUÌ, ORIETTA DAL CANTON, FERDINANDO GARETTO, MANUELA BISCARDI, ELISA BERNO, ALESSANDRO COMANDONE
Anticancer Research Jul 2008, 28 (4C) 2327-2332;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Weekly Irinotecan Plus Protracted Venous Fluorouracil Infusion (WI-FI) in Advanced Colorectal Cancer: A Phase II Study
CRISTIANO OLIVA, PAOLO POCHETTINO, PAOLA BERGNOLO, ANTONELLA BOGLIONE, SIMONA CHIADÒ CUTIN, MANUELA INGUÌ, ORIETTA DAL CANTON, FERDINANDO GARETTO, MANUELA BISCARDI, ELISA BERNO, ALESSANDRO COMANDONE
Anticancer Research Jul 2008, 28 (4C) 2327-2332;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Palliative Radiotherapy for Large Osteolytic Metastatic Tumors Involving the Iliac Bone: A Report of 16 Cases
  • Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma
  • The Long-term Outcomes of Borderline Resectable T3 in Locally Advanced Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Triplet Chemotherapy
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire